Deutsche Bank Ag\ Janux Therapeutics, Inc. Transaction History

Deutsche Bank Ag\

$240 Billion
Q3 2024

A detailed history of Deutsche Bank Ag\ transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Deutsche Bank Ag\ holds 19,117 shares of JANX stock, worth $961,776. This represents 0.0% of its overall portfolio holdings.

Number of Shares

19,117

Previous 12,424 53.87%

Holding current value

$961,776

Previous $520,000 66.92%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$35.29 - $50.26 $236,195 - $336,390	6,693 Added 53.87%	19,117 $868,000
Q2 2024 Aug 14, 2024	BUY	$35.12 - $64.78 $200,148 - $369,181	5,699 Added 84.74%	12,424 $520,000
Q1 2024 May 15, 2024	SELL	$7.93 - $49.75 $1,966 - $12,338	-248 Reduced 3.56%	6,725 $253,000
Q2 2023 Aug 14, 2023	SELL	$11.08 - $15.92 $38,613 - $55,481	-3,485 Reduced 33.32%	6,973 $82,000
Q1 2023 May 15, 2023	BUY	$11.25 - $22.21 $25,256 - $49,861	2,245 Added 27.33%	10,458 $126,000
Q4 2022 Feb 13, 2023	BUY	$11.1 - $18.26 $1,265 - $2,081	114 Added 1.41%	8,213 $108,000
Q3 2022 Nov 14, 2022	SELL	$10.82 - $16.84 $12,367 - $19,248	-1,143 Reduced 12.37%	8,099 $110,000
Q2 2022 Aug 11, 2022	SELL	$9.52 - $15.65 $12,909 - $21,221	-1,356 Reduced 12.79%	9,242 $113,000
Q1 2022 May 13, 2022	BUY	$13.24 - $20.24 $26,215 - $40,075	1,980 Added 22.98%	10,598 $152,000
Q4 2021 Feb 11, 2022	BUY	$15.44 - $27.32 $6,685 - $11,829	433 Added 5.29%	8,618 $170,000
Q3 2021 Nov 04, 2021	BUY	$20.7 - $34.69 $169,429 - $283,937	8,185 New	8,185 $178,000

Others Institutions Holding JANX

# of Institutions

166

Shares Held

37.6M

Call Options Held

85.3K

Put Options Held

654K

View Full List

About Janux Therapeutics, Inc.

Ticker JANX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,663,000
Market Cap $2.1B
Description
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...

More about JANX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.

Account